Rapid preparation and characterization of pan-sarbecovirus mRNA vaccine candidates based on the receptor binding domain  

作　　者：Mei Wu Tian-Shu Cao Xiao-Chuan Xiong Tao Ming Pan-Deng Shi Rong-Rong Zhang Qing Ye Cheng-Feng Qin 

机构地区：[1]State Key Laboratory of Pathogen and Biosecurity,AMMS,Beijing 10071,China

出　　处：《Virologica Sinica》2025年第1期144-146,共3页中国病毒学(英文版)

基　　金：supported by the National Key Research and Development Program of China(2021YFC2302400);the National Natural Science Foundation of China(82241069 and 82350801);supported by the National Science Fund for Distinguished Young Scholar(81925025);the Innovation Fund for Medical Sciences(2019-I2M-5-049)from the Chinese Academy of Medical Sciences;sponsored by Beijing Nova Program(20240484525).

摘　　要：Dear Editor,The pandemic of coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),continues despite extensive efforts to control viral transmission.Meanwhile,the emergence of SARS-CoV-2 variants with antigenically divergence in viral protein dampens the efficacy of authorized vaccines,leading to the breakthrough infections in vaccinated population(Cao et al.,2021,2022;Tuekprakhon et al.,2022;Xiang et al.,2022).Moreover,diverse sarbecoviruses in bats and pangolins have been discovered and isolated(Ge et al.,2013;Xiao et al.,2020).Some of these viruses have exhibited efficient binding to human angiotensin-converting enzyme 2(hACE2)(Xiao et al.,2020;Liu et al.,2021;Temmam et al.,2022),highlighting the risk of spillover from wild animals to human.Thus,the development of pan-sarbecovirus vaccines is of high priority.

关 键 词：severe acute respiratory syndrome coronavirus breakthrough infections receptor binding domain vaccine coronavirus disease PANDEMIC 

分 类 号：R392[医药卫生—免疫学]